ACOSOG Z1071 Study

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerThe ACOSOG Z1071 (Alliance) Clinical Trial

According to the Z1071 study, for patients who had positive nodes pre-chemotherapy and then had a sentinel node biopsy, the false-positive rate was less than 10% if dual tracer was used, greater than two sentinel nodes were removed, and any clipped nodes were included.

If only one lymph node was removed, the false-negative rate was unacceptably high and further axillary surgery was needed. Until the Alliance 11202 trial is completed, the standard treatment remains an axillary dissection for positive nodes after chemotherapy.

References

Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013; 310(14): 1455-1461. doi: 10.1001/jama.2013.278932.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s